Eupraxia Pharmaceuticals Inc. (EPRX)
The price, the headline numbers and the latest news, in one place.
Eupraxia Pharmaceuticals Inc. (EPRX) Stock Price, Analysis & Data
| Bid | 5.27 |
| Market Cap | 466M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -52.7M |
| 1.50 | |
| -1.02 | |
| n/a | |
| -6.78 | |
| P/B (ttm) | 4.54 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 3, 2026 |
| Ask | 9.07 |
| Volume | 151,554 |
| Avg. Volume (20D) | 373,446 |
| Open | 6.42 |
| Previous Close | 6.46 |
| Day's Range | 6.33 - 6.53 |
| 52-Week Range | 5.15 - 9.32 |
| Analyst | Strong<br>Buy |
| Price Target | 15.75 (148.42%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About EPRX
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical ...
Financial Performance
In 2025, Eupraxia Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -38.58M, an increase of 51.26%.
Financial StatementsAnalyst Forecast
According to 10 analyst ratings, the average rating for EPRX stock is "Strong Buy". The 12-month stock price forecast is 15.75, which is upside of 148.42% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.23 misses estimates by 0.00, with -9.52% YoY decline.
Analysts project revenue of ... Upgrade
